Semaglutide is often given as a weekly injection, and its important to maintain a regular schedule for both medications to get the best results
In some cases, already obese patients are purposely gaining weight so they can reach the required body-mass index, a measure comparing weight to height, to qualify for coverage
Semaglutide is the active ingredient behind blockbuster therapies such as Ozempic and Wegovy developed by Novo Nordisk
As of December 2025, retatrutide is not approved by the FDA for any indication
Your starting weight, diet, exercise routine, and overall health all influence how quickly you see results
Immune therapies for neurological disorders Currently, there are no FDA-approved immunomodulatory therapies for stroke